The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Novo Nordisk stock was jumping Monday after the company said late Friday that its weight-loss medicine Wegovy had been approved to treat a serious form of liver disease. It’s a welcome boost for the ...

Air Canada says it now plans to resume flights on Monday evening after a planned resumption of service on Sunday afternoon ...

Morning. Today, we examine the plush pay packages of health care’s top CEOs in 2024. Also, we discuss Stealth BioTherapeutics’ efforts to rally support behind its Barth syndrome drug, and hear more ...

Artificial intelligence could generate annual net benefits of roughly $920 billion for S&P 500 companies, according to Morgan Stanley (NYSE:MS).

Bernstein has upgraded Toyota (TYO:7203) (NYSE:TM) to Outperform from Market-Perform and raised its price target to 3,500 Japanese yen from ¥2,550 yen.

Stock futures are modestly lower this morning, following the major benchmarks' second consecutive weekly wins. Central bank members will be heading to Jackson Hole, Wyoming for the annual economic ...